Pyxis Oncology, Inc. (PYXS): Net Income

Annual figures by period end, from SEC filings.

-$79.62M

Year ended 2025-12-31

-$88.73M

Trailing 12 months to 2026-06-30

2020-12-31 Net Income (USD) 2025-12-31

Period ended	Net Income	Change YoY	Source filing
2025-12-31	-$79.62M	n/m	2026-03-23, From 2025-01-01
2024-12-31	-$77.33M	n/m	2026-03-23, From 2024-01-01
2023-12-31	-$73.79M	n/m	2025-03-18, From 2023-01-01
2022-12-31	-$120.72M	n/m	2024-03-21, From 2022-01-01
2021-12-31	-$75.97M	n/m	2023-03-22, From 2021-01-01
2020-12-31	-$12.83M	n/a	2022-03-29, From 2020-01-01

Net Income at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Net Income	Change YoY
Pyxis Oncology, Inc. (PYXS)	2025-12-31	-$79.62M	n/m
CV Sciences, Inc. (CVSI)	2025-12-31	-$958.0K	n/m
Arbutus Biopharma Corp (ABUS)	2025-12-31	-$33.50M	n/m
Opus Genetics, Inc. (IRD)	2025-12-31	-$49.59M	n/m
Palatin Technologies Inc (PTN)	2026-06-30	-$8.38M	n/m
Tonix Pharmaceuticals Holding Corp. (TNXP)	2025-12-31	-$124.02M	n/m
Evommune, Inc. (EVMN)	2025-12-31	-$68.87M	n/m
Emmaus Life Sciences, Inc. (EMMA)	2025-12-31	-$7.49M	n/m
Prelude Therapeutics Inc (PRLD)	2025-12-31	-$99.50M	n/m

Compare PYXS, CVSI, ABUS, IRD side by side · Screen every company in Pharmaceutical Preparations ↗